Nexia Biotechnologies Inc. Company Center

Nexia Biotechnologies Inc. (TSX: NXB) develops and manufactures complex recombinant proteins for military and civilian applications. Protexia™, Nexia's lead pharmaceutical product, is a recombinant form of human butyrylcholinesterase (BChE) that is being developed as a military battlefield protection system (prophylaxis) and a medical countermeasure (rescue therapy) for civilian homeland security. BioSteel® is based on recombinant spider silk proteins and is being developed for nanotechnology applications. Nexia has developed a proprietary expression system based on transgenic goats to produce recombinant proteins in an efficient and cost-effective way.

---

 

Last update by Jeffrey Turner